팬젠
Financials
Valuation Metrics
팬젠's Market Cap is ₩572B. At end of 2025 it was ₩757B. Ranked #1588 of 2,410 in KR market (top 66%), #933 of 1,631 on KOSDAQ (top 57%), #175 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 76%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 57.23B KRW | KR#1,588/2,410 Sec#175/231 |
| Revenue | 14.18B KRW | KR#2,219/2,410 Sec#168/231 |
| Net Income | 1.13B KRW | KR#1,470/2,410 Sec#101/231 |
| Total Assets | 33.28B KRW | KR#2,308/2,410 Sec#216/231 |
| Net Assets | 30.75B KRW | KR#2,160/2,410 Sec#193/231 |
| Employees | 75 | KR#1,836/2,410 Sec#158/231 |
| Value | ||
| P/E | 50.67x | KR#1,431/2,410 Sec#92/231 |
| P/B | 1.87x | KR#1,959/2,410 Sec#144/231 |
| P/S | 4.05x | KR#2,117/2,410 Sec#141/231 |
| EV/EBITDA | 230.39x | KR#1,535/2,410 Sec#106/231 |
| FCF Yield | -0.65% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | 3.68% | KR#1,266/2,410 Sec#87/231 |
| ROA | 3.40% | KR#981/2,410 Sec#77/231 |
| Op. Margin | 1.66% | KR#1,425/2,410 Sec#101/231 |
| Revenue Growth | -10.59% | KR#1,934/2,410 Sec#179/231 |
| Earnings Growth | -50.72% | KR#1,056/2,410 Sec#70/231 |
| Financial Health | ||
| Debt Ratio | 8.22% | KR#96/2,410 Sec#21/231 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/231 |
| FCF | -373.0M KRW | KR#1,246/2,410 Sec#95/231 |
| Cash | 3.01B KRW | KR#2,157/2,410 Sec#203/231 |
| Current Ratio | 9.55x | KR#106/2,410 Sec#25/231 |
| Net Debt/EBITDA | -12.78x | KR#33/2,410 Sec#2/231 |
| Performance | ||
| 1Y Return | -28.05% | KR#1,318/2,410 Sec#96/231 |
| 1M Return | -11.56% | KR#1,018/2,410 Sec#100/231 |
| From 52W High | -50.12% | KR#1,099/2,410 Sec#85/231 |
| 1Y MDD | -42.17% | KR#611/2,410 Sec#42/231 |
| Trading | ||
| Volume | 4,530 shares | KR#1,639/2,410 Sec#168/231 |
| Trading Value | 19.2M KRW | KR#1,622/2,410 Sec#171/231 |
| Foreign Own. | 7.20% | KR#618/2,410 Sec#54/231 |
| Per Share | ||
| EPS | 84 KRW | KR#1,457/2,410 Sec#99/231 |
| BPS | 2,275 KRW | KR#2,014/2,410 Sec#165/231 |
Company Info
PanGen, established in 2010 as a spin-off, was listed on KOSDAQ as a technology growth company in 2016. The company provides biosimilar EPO drug production and sales, biopharmaceutical contract manufacturing, and development technology transfer services, leveraging its PanGen CHO-TECH™ technology and GMP facilities. Its EPO drugs are sold in Asia and Saudi Arabia, and it has completed clinical Phase 3 sample production for Hemophilia A treatment, along with non-clinical trials for macular degeneration treatment and anti-cancer adjuvants. PanGen is headquartered in Suwon-si, Gyeonggi-do.